feedback

Course Director

Prof. Xavier Montalban
Prof. Xavier Montalban

Chairman and Director
Neurology-Neuroimmunology Department & Neurorehabilitation
Multiple Sclerosis Centre of Catalonia (Cemcat)
Vall d’Hebron Barcelona Hospital Campus
Barcelona, Spain

Faculty

Amit Bar-Or
Amit Bar-Or, MD, FRCPC

Melissa and Paul Anderson Distinguished Professor
Director, Center for Neuroinflammation and Experimental Therapeutics
Chief, Multiple Sclerosis Division, Department of Neurology
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
President, International Society for Neuroimmunology
Philadelphia, Pennsylvania

Prof. Dr. med. Dr. h. c. mult. Ludwig Kappos
Prof. Dr. med. Dr. h. c. mult. Ludwig Kappos

Chair Neurology
Departments of Medicine, Biomedicine, Clinical Research and Biomedical Engineering
University Hospital Basel
Basel, Switzerland

Accredited by

Penn State College of Medicine

View Activity Materials

Activity Description and Educational Objectives

Advances—in understanding of disease pathogenesis, emerging therapies, and new imaging approaches—have the potential to significantly improve care of individuals with multiple sclerosis (MS). The recognition of a central role for B lymphocytes in MS pathogenesis and development of two classes of therapeutic agents that target B cells—anti-CD20 antibodies and Bruton tyrosine kinase (BTK) inhibitors—facilitates the use of more novel disease-modifying therapies (DMTs). In addition, advances in imaging approaches can enhance diagnosis, disease monitoring, and treatment guidance. In this activity, based on a recent live webcast, our expert faculty will offer insight into the pathogenesis of MS, targeting B cells for the treatment of MS, and novel imaging approaches for monitoring disease status and treatment in relapsing MS.

Upon completion of this activity, participants should be better able to:
  • Summarize current perspectives on the roles of diverse cell types (eg, B and T lymphocytes, microglia, astrocytes) in the pathogenesis of relapsing MS
  • Apply individualized treatment regimens for relapsing MS by incorporating recent information on new and emerging therapies that target B lymphocytes
  • Compare available and novel imaging approaches for monitoring disease status and facilitating treatment decisions in relapsing MS

Target Audience

This activity has been designed to meet the educational needs of neurologists and other clinicians involved in the management of multiple sclerosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 29, 2020 - October 28, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair
Prof. Xavier Montalban
Chairman and Director
Neurology-Neuroimmunology Department & Neurorehabilitation
Multiple Sclerosis Centre of Catalonia (Cemcat)
Vall d’Hebron Barcelona Hospital Campus
Barcelona, Spain

Prof. Xavier Montalban has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Actelion Pharmaceuticals Ltd; Alexion Pharmaceuticals, Inc.; Biogen; Celgene Corporation; EMD Serono, Inc.; F. Hoffman-La Roche Ltd.; Genzyme Corporation; Immunic, Inc.; MedDay Pharmaceuticals; Merck & Co., Inc.; Mylan Inc.; NervGen Pharma Corp.; Sanofi; Teva Pharmaceutical Industries Ltd.; and TG Therapeutics.
Grant/Research Support from Actelion Pharmaceuticals Ltd; Alexion Pharmaceuticals, Inc.; Biogen; Celgene Corporation; EMD Serono, Inc.; F. Hoffman-La Roche Ltd.; Genzyme Corporation; Immunic, Inc.; MedDay Pharmaceuticals; Merck & Co., Inc.; Mylan Inc.; NervGen Pharma Corp.; Sanofi; Teva Pharmaceutical Industries Ltd.; and TG Therapeutics.

Faculty
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson Distinguished Professor
Director, Center for Neuroinflammation and Experimental Therapeutics
Chief, Multiple Sclerosis Division, Department of Neurology
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
President, International Society for Neuroimmunology
Philadelphia, Pennsylvania

Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen; Celgene Corporation/Receptos Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Janssen Pharmaceuticals, Inc./Actelion Pharmaceuticals Ltd; Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC/Genzyme Corporation.
Grant/Research Support from Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Novartis Pharmaceuticals Corporation.

Prof. Dr. med. Dr. h. c. mult. Ludwig Kappos
Chair Neurology
Departments of Medicine, Biomedicine, Clinical Research and Biomedical Engineering
University Hospital Basel
Basel, Switzerland

Prof. Dr. med. Dr. h. c. mult. Ludwig Kappos has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Actelion Pharmaceuticals Ltd.; Allergan plc; Almirall, S.A; Baxalta; Bayer AG; Biogen; Celgene Corporation/Receptos; CSL Behring; Desitin Arzneimittel GmbH; EXECMED; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd.; Genzyme Corporation; JT International SA; Minoryx Therapeutics SL; Merck & Co., Inc.; Novartis AG; Pfizer AG; Sanofi; Santhera Pharmaceuticals; and Teva Pharmaceutical Industries Ltd.
Grant/Research Support from Bayer AG; Biogen; The European Union; Novartis AG; Inno-Suisse; Roche Research Foundations; The Swiss MS Society; and The Swiss National Research Foundation.
Other Financial or Material Support from steering committees for Actelion Pharmaceuticals Ltd.; Allergan plc; Almirall, S.A; Baxalta; Bayer AG; Biogen; Celgene Corporation/Receptos; CSL Behring; Desitin Arzneimittel GmbH; EXECMED; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd.; Genzyme Corporation; JT International SA; Minoryx Therapeutics SL; Merck & Co., Inc.; Novartis AG; Pfizer AG; Sanofi; Santhera Pharmaceuticals; and Teva Pharmaceutical Industries Ltd. License fees for Neurostatus-UHB products.

Medical Directors
Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kimberly McFarland, PhD
PVI, PeerView Institute for Medical Education

Kimberly McFarland, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Angela McIntosh, PhD
PVI, PeerView Institute for Medical Education

Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6658-21-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from EMD Serono, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.